Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|July 30, 2026 (Updated: July 30, 2026)

The BioPharm Brief: Expansion, Engineering, and Evolution

Listen
0:00 / 0:00

This episode of The BioPharm Brief explores how next-generation biologics are reshaping oncology and autoimmune disease, from a first-line antibody-drug conjugate filing and a novel ADC entering the clinic to a major investment in in vivo CAR-T technology.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today's stories highlight three different ways companies are advancing the next generation of biologic therapies. From expanding the role of antibody-drug conjugates in breast cancer to refining ADC design for solid tumors and reimagining CAR-T therapy for autoimmune disease, the focus is on making advanced therapies more precise, more accessible, and more effective.

First, Kelun-Biotech has submitted a supplemental New Drug Application to China's National Medical Products Administration seeking approval of sacituzumab tirumotecan, or sac-TMT, in combination with pembrolizumab as a first-line treatment for PD-L1-positive advanced triple-negative breast cancer. The filing follows positive Phase 3 data showing the combination significantly improved progression-free survival compared with pembrolizumab and chemotherapy. If approved, the indication would further expand the role of TROP2-directed antibody-drug conjugates in earlier lines of cancer treatment and intensify competition within the rapidly evolving ADC field.

Next, Iksuda Therapeutics has received FDA clearance of its Investigational New Drug application for IKS04, a CA242-directed antibody-drug conjugate for gastrointestinal cancers. Beyond the molecule itself, the program introduces an accompanying dosing strategy designed to improve solid tumor penetration by high-potency ADCs. The company says the approach combines tumor-selective linker chemistry with an optimized administration regimen intended to improve therapeutic delivery while reducing off-target toxicity. Phase 1 testing in patients with GI cancers is now set to begin.

Finally, Johnson & Johnson is making a major bet on the future of cell therapy through a collaboration with Sail Biomedicines. The agreement includes a $785 million upfront commitment and an exclusive option to acquire the company for up to $2.58 billion. Unlike conventional CAR-T therapies that require cells to be removed, engineered, and reinfused, Sail's platform is designed to generate CAR-T cells directly inside the patient's body. The companies aim to apply this in vivo approach to immune-mediated diseases, potentially simplifying manufacturing while expanding access to cell-based therapies beyond oncology.

From broadening ADC use in frontline cancer care to improving how these therapies reach tumors and rethinking CAR-T manufacturing altogether, today's stories reflect an industry focused not only on developing new biologics, but also on engineering smarter ways to deliver them.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • Kelun-Biotech advances sac-TMT toward first-line use in triple-negative breast cancer following positive phase 3 results.
  • Iksuda moves its next-generation ADC into the clinic with an FDA-cleared trial and a novel dosing strategy.
  • Johnson & Johnson invests in in vivo CAR-T technology aimed at simplifying cell therapy for autoimmune disease.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more